Endocrinology and Metabolism Research Center, Tehran University of Medical Sciences, 5th Floor, Shariati Hospital, North Kargar Ave., 14114, Tehran, Iran.
J Bone Miner Metab. 2011 Mar;29(2):186-92. doi: 10.1007/s00774-010-0205-0. Epub 2010 Jul 3.
The aim of our study was to investigate the relationship between maternal and fetal bone turnover markers and folic acid supplementation during pregnancy. In an observational study performed in Tehran University of Medical Sciences related hospitals, 113 healthy pregnant women with gestational age between 8 and 12 weeks and aged between 15 and 42 years were recruited and followed until delivery time. The participants were divided into two groups; women who took 1 mg of folic acid daily supplement from the beginning of the pregnancy until the end of the second trimester entered into group I and women who choose to continue their daily intake of folic acid until the delivery time entered into group II. The two groups were matched based on the maternal anthropometric data, energy, calcium and vitamin D intake. Following the delivery, venous blood samples were collected from mothers and umbilical cords of the neonates. Maternal and fetal serum concentrations of 25-hydroxy vitamin D3, PTH, osteocalcin (OC), crosslaps and maternal serum level of homocysteine, folate, soluble receptor activator of NF-kappaB ligand (sRANKL), osteoprotegerin (OPG), calcium, and phosphate were measured. Measured birth outcome parameters included weight, length, head circumference, appearance, and respiration. With regard to maternal assessment, the serum levels of OC and OPG and folate were significantly higher in group II compared to group I, while the serum levels of RANKL and homocysteine were significantly higher in group I. We did not find significant differences in serum levels of 25-OH vitamin D, PTH, crosslaps, calcium, or phosphate between the two groups. The neonates from mothers recruited in group II had higher (but not significantly) serum level of OC. We observed that the neonates born from mothers in group II had overall better birth outcome parameters and apgar scores compare to the neonates born from mothers in group I. Our results show that daily supplementation of folic acid during pregnancy could have a positive impact on the bone turnover markers in mothers and their newborns. This may suggest that both pregnant mothers and their fetuses could benefit from positive effects of folic acid taken during the whole period of pregnancy.
我们的研究目的是探讨孕妇骨转换标志物与叶酸补充之间的关系。在德黑兰医科大学附属医院进行的一项观察性研究中,招募了 113 名孕龄 8-12 周、年龄 15-42 岁的健康孕妇,并对其进行随访直至分娩。参与者被分为两组;从妊娠开始至妊娠中期末每天服用 1 毫克叶酸的女性进入 I 组,选择继续每日摄入叶酸直至分娩的女性进入 II 组。两组根据母体人体测量学数据、能量、钙和维生素 D 摄入量进行匹配。分娩后,从母亲和新生儿脐带中采集静脉血样。测量母亲和胎儿血清中的 25-羟维生素 D3、甲状旁腺激素、骨钙素 (OC)、交联胶原 (Crosslaps) 和母体血清同型半胱氨酸、叶酸、可溶性核因子 κB 受体激活剂配体 (sRANKL)、骨保护素 (OPG)、钙和磷的水平。测量的出生结局参数包括体重、长度、头围、外观和呼吸。就母体评估而言,与 I 组相比,II 组的血清 OC 和 OPG 以及叶酸水平显著升高,而 I 组的血清 RANKL 和同型半胱氨酸水平显著升高。两组间血清 25-OH 维生素 D、甲状旁腺激素、Crosslaps、钙或磷水平无显著差异。来自 II 组母亲的新生儿血清 OC 水平较高(但无统计学意义)。我们观察到,与来自 I 组母亲的新生儿相比,来自 II 组母亲的新生儿整体出生结局参数和 Apgar 评分更好。我们的结果表明,孕妇在孕期每日补充叶酸可能对母亲及其新生儿的骨转换标志物产生积极影响。这可能表明,孕妇及其胎儿都可以从整个孕期摄入叶酸中受益。